TransCode Therapeutics (NASDAQ:RNAZ – Get Free Report) is expected to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect TransCode Therapeutics to post earnings of ($3.21) per share for the quarter.
TransCode Therapeutics Trading Down 5.8 %
Shares of NASDAQ RNAZ opened at $0.49 on Monday. The firm’s 50-day moving average price is $5.01 and its 200-day moving average price is $216.88. TransCode Therapeutics has a 1-year low of $0.49 and a 1-year high of $66.33.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of TransCode Therapeutics in a research note on Thursday, March 13th.
About TransCode Therapeutics
TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.
Recommended Stories
- Five stocks we like better than TransCode Therapeutics
- What is the Dogs of the Dow Strategy? Overview and Examples
- Venezuelan Tariffs Could Power These 3 Diesel-Driven Winners
- How to Calculate Stock Profit
- MarketBeat Week in Review – 03/24 – 03/28
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Should You Buy UPS Stock Now? Deep Dive Into Its 5-Year Low
Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
